Sanara Capital

Founder and Managing Partner Assaf Barnea leads investment decisions. He built the predecessor vehicle, Sanara Ventures, starting in 2015 with backing from Philips and Teva. Barnea is supported by a team of venture partners stationed in Israel, the United States, Europe, and China.

Sanara Ventures, launched in 2015, was a seed-stage investment platform backed by Philips and Teva. Sanara Capital, founded in 2023, is a follow-on fund that targets A and B rounds. The two entities share a portfolio of nearly 20 companies and the same founder, Assaf Barnea.

The firm focuses on Series A and Series B financing rounds. Its predecessor, Sanara Ventures, handled seed-stage investing, giving the combined portfolio coverage from early formation through growth-stage clinical and regulatory execution.

No. The firm targets Israeli-related startups, meaning companies with Israeli founders, technology, or operations, but invests in them regardless of where they are domiciled. Venture partners on the team are based in the United States, Europe, and China.

Teva and Philips are strategic partners that have backed the Sanara platform since 2015. They provide industry connections, market knowledge, and support across digital health, medical devices, and bio-convergence, though the firm does not disclose the governance or economic terms of the relationship.

Sanara's pipeline is fed by a decade-old network built through Sanara Ventures, a 120-member global advisory board of clinicians and executives, and the corporate reach of Teva and Philips. The firm has not disclosed whether it accepts third-party broker or inbound-only deal flow.

Sanara has not publicly stated a formal co-investment policy. Given its A- and B-round focus and corporate backing, it likely syndicates with other venture and corporate investors, but no specific co-investors have been disclosed in public materials.